Results 191 to 200 of about 63,834 (278)
GLP‐1 agonists and the gut microbiome: A bidirectional relationship
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath +2 more
wiley +1 more source
Efficacy and safety of Shatavari root extract in women with Polycystic Ovarian Syndrome: a randomized, double-blind, placebo-controlled trial. [PDF]
Mhatre Y +4 more
europepmc +1 more source
Molecular profiles and outcomes of CR rate in 74 cases. ABSTRACT Objective To investigate the impact of various molecular characteristics on the outcomes of fertility‐preserving therapy in patients with endometrial cancer (EC) and atypical endometrial hyperplasia (AEH).
Xue‐Qian Qian +4 more
wiley +1 more source
Severe Hyperandrogenism Secondary to Polycystic Ovarian Syndrome in a Gender-diverse Adolescent. [PDF]
Schneider D +3 more
europepmc +1 more source
Luteolin attenuates noise‐induced auditory hair cell loss, as well as TBHP‐induced oxidative stress and apoptosis. EGR1 modulates the transcription of SPRY4; the expression levels of both factors are upregulated following TBHP exposure, and this inductive effect is abrogated by luteolin treatment.
Jia‐ning Guo +10 more
wiley +1 more source
Correction: Myoinositol Versus Metformin in the Treatment of Polycystic Ovarian Syndrome: A Systematic Review. [PDF]
Bodepudi R +9 more
europepmc +1 more source
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson +4 more
wiley +1 more source
Pathophysiology of androgen-associated endothelial cell dysfunction in phenotype A polycystic ovarian syndrome revealed by iPSCs modeling. [PDF]
Wu CE +6 more
europepmc +1 more source
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott +7 more
wiley +1 more source
Identification and validation of biomarkers associated with glycolysis in polycystic ovarian syndrome. [PDF]
Zhu R, Yu X, Li Y.
europepmc +1 more source

